Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more
Mesoblast Limited (LWB) - Total Liabilities
Latest total liabilities as of June 2025: €187.24 Million EUR
Based on the latest financial reports, Mesoblast Limited (LWB) has total liabilities worth €187.24 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mesoblast Limited - Total Liabilities Trend (2014–2025)
This chart illustrates how Mesoblast Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mesoblast Limited Competitors by Total Liabilities
The table below lists competitors of Mesoblast Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
alstria office REIT-AG
XETRA:AOX
|
Germany | €2.93 Billion |
|
Shanghai Zijiang Enterprise Group Co Ltd
SHG:600210
|
China | CN¥6.45 Billion |
|
K.P.R. Mill Limited
NSE:KPRMILL
|
India | ₹7.34 Billion |
|
Chengdu Olymvax Biopharmaceuticals Inc. A
SHG:688319
|
China | CN¥976.63 Million |
|
Sichuan Jiuzhou Electronic Co Ltd
SHE:000801
|
China | CN¥4.05 Billion |
|
Zhejiang Jiahua Energy Chemical Industry Co Ltd
SHG:600273
|
China | CN¥3.52 Billion |
|
GMéxico Transportes S.A.B. de C.V
PINK:GMXTF
|
USA | $72.07 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Mesoblast Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mesoblast Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mesoblast Limited (2014–2025)
The table below shows the annual total liabilities of Mesoblast Limited from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €187.24 Million | -0.82% |
| 2024-06-30 | €188.80 Million | +12.66% |
| 2023-06-30 | €167.58 Million | +1.50% |
| 2022-06-30 | €165.10 Million | +1.09% |
| 2021-06-30 | €163.32 Million | -11.37% |
| 2020-06-30 | €184.28 Million | +7.72% |
| 2019-06-30 | €171.06 Million | +16.82% |
| 2018-06-30 | €146.44 Million | +5.41% |
| 2017-06-30 | €138.92 Million | -10.87% |
| 2016-06-30 | €155.86 Million | -50.33% |
| 2015-06-30 | €313.78 Million | +1.56% |
| 2014-06-30 | €308.95 Million | -- |